New Products and Services
This page contains announcements of new pathology products and services from advertisers. Most announcements are posted for 90 days and then removed. To view new Jobs, Fellowships, Conferences, or Books, please see those pages. For more information, contact Nat Pernick at NatPernick@Hotmail.com or at 248/646-0325.
26 June 2009: Clarient, Inc. announces a new test for the epidermal growth factor receptor (EGFR) mutation, to help physicians select the proper therapy for patients with non-small cell lung cancer (NSCLC). “Our new EGFR mutation test can be used as a predictive molecular biomarker to explain why a subset of patients with non-small cell lung cancer may respond to EGFR tyrosine kinase inhibitor (TKI) therapies,” said Clarient Chief Executive Officer Ron Andrews.
EGFR activates an important pathway that leads to cell proliferation, lack of differentiation, enhanced cell survival and gene transcription. A large body of experimental and clinical work supports the view that EGFR is an important target for cancer therapy. There are a number of drugs used for the treatment of NSCLC. Several recent publications reported that virtually all responders to these drugs have well documented mutations in the EGFR gene. Mutations on EGFR can be seen in about 10-15 percent of patients.
Click here for more information on Clarient.
_______________________________________________
18 June 2009: Photodyne Technologies is a manufacturer of specialized photographic machines for use in grossing, pathology and forensic labs, and other macro photography applications. Our new macro-photography and grossing units have an optional low voltage D.C. operation, for enhanced safety. The units are supplied with top of the line digital cameras, with resolution of 8 to 15 megapixels and higher. The system comes with proprietary software and connects directly to the user’s computer through a USB port, allowing the user to take pictures directly from the computer in real time, with adjustments in the scene as necessary. All major attributes of the camera are controllable from the computer as well.
Once the picture is snapped, the data are transferred to the hard drive through the USB port and stored in the user’s specified location, and the pictures are then ready to be used for lectures and presentations, archiving, email attachments, research and more.
Visit us online at www.photodyne.com or contact us at 800-660-2147 or hrzc@earthlink.net for more information.
_______________________________________________
June 17, 2009: Modern Pathology, the official journal of the United States and Canadian Academy of Pathology (USCAP), announces the following free articles in its June 2009 issue:
MMF related histologic changes in colonic biopsies
AITL with hyperplastic follicles
Modern Pathology's main focus is original papers reporting innovative clinical and translational research in the pathology of human disease. Access to all content is FREE 12 months post-publication. Visit the journal website at www.modernpathology.org.
_______________________________________________
June 17, 2009: Laboratory Investigation, the official journal of the United States and Canadian Academy of Pathology, presents the following free articles in its June 2009 issue:
Cellular switch for life and death
Moderating the acute phase response
Mechanisms of parenchymal injury and signaling pathways in ectatic ducts of CP
Laboratory Investigation is an international journal owned by The United States and Canadian Academy of Pathology and edited by a board appointed by the Council of the Academy. Laboratory Investigation offers prompt publication of high-quality original research in all biomedical disciplines relating to the understanding of human disease and the application of new methods to the diagnosis of disease. Visit online at Laboratory Investigation.
______________________________________________
15 May 2009: Aperio is pleased to introduce SecondSlide - an innovative digital slide sharing service for pathology. SecondSlide makes it easy for you to share slides with anyone you choose, regardless of geographical location. You can send digital slides, documents, and relevant data to SecondSlide where they can be managed and shared for use in a variety of applications, including consultations, quality assurance, tumor boards, and publication support.
With SecondSlide, you can improve turnaround time for consultations, eliminate glass slide logistics, provide pathology services to remote hospitals, and gain access to subspecialty expertise.
Click on the data sheet image to learn more.
For more information, click here or contact us at info@aperio.com or 866.478.4111. Be sure to ask about our Two-Month FREE Trial Promotion!
__________________________________________
11 May 2009: Clarient, Inc. announces a new breast cancer test to identify the probability of recurrence and assess the need for chemotherapy. The new prognostic test, Clarient Insight® Dx Breast Cancer Profile, has been clinically validated for women with early-stage, hormone-receptor-positive breast cancer. It categorizes patients as either high or low risk using tumor size, tumor grade, lymph node status, ER, PR, HER2, EGFR, BCL2, p53, and MYC. This information is combined with a proprietary algorithm to produce a risk score.
The test was clinically validated using patients from the Royal Perth Hospital in Western Australia. These results also correlated with earlier findings presented in the International Journal of Cancer in February 2009 and at the San Antonio Breast Cancer Symposium in December 2008.
Click here for more information on the test, or here for more information on Clarient.
__________________________________________
27 April 2009: Clarient, Inc. announces that it has been granted an exclusive intellectual property license from the Indiana University Research and Technology Corporation to commercialize the FOXA1 biomarker, which predicts the likelihood of recurrence and long-term, disease-free breast cancer survival. The FOXA1 marker, also known as forkhead box A1, is a gene known to cause breast cancer. Data presented at the 2009 USCAP meeting demonstrated that the expression of FOXA1, now known to be an estrogen receptor associated transcription factor, correlated with Oncotype Dx®. In 79 ER-positive, node-negative breast cancer patients, researchers found that FOXA1 expression identified the same low risk, ER-positive, node negative patients who can be spared toxic chemotherapy (P=0.002).
“FOXA1 has also demonstrated an ability to differentiate between unique sets of breast cancer characteristics, which include luminal A and B subtypes,” said Ken Bloom, M.D., Clarient’s Chief Medical Officer. “Although both luminal subtype A and B correspond to ER-positive breast cancers, we have always known that luminal A subtype patients are associated with a significantly better prognosis in breast cancer. Clarient’s agreement to license FOXA1 from IURTC provides for another strong marker to help identify these luminal A subtypes.”
Click here for more information on Clarient.
__________________________________________
26 April 2009: Impac Software has named Timothy J. Dolan, Pathology Information System Manager at Roswell Park Cancer Institute in Buffalo, New York as 2009 Laboratory Professional of the Year. The annual award is part of Impac Software’s celebration of National Medical Laboratory Professionals Week, April 19-25, 2009. He was recognized for his 18 years of exceptional service, including managing the implementation of Impac Software’s laboratory information system, PowerPath®.
For more information, please click here, or contact Julie DeSantis, Market Manager, Impac Software 408-830-8083 or jdesantis@impac.com
__________________________________________
20 April 2009: Mopec is pleased to introduce its newest product, 10%Neutral Buffered Formalin. Premixed Neutral Buffered Formalin takes the mess out of mixing and pouring. Shelf life is 2 years. Mopec offers four convenient sizes: 1 Gallon, 5 Gallon Cubitainer, 30 Gallon Drum and a 55 Gallon Drum. For a limited time, Mopec has introductory pricing.
For more information, please click here, contact sales@mopec.com or call one of our friendly and knowledgeable customer service representatives at 800.362.8491.
_______________________________________________
20 April 2009: Modern Pathology, the official journal of the United States and Canadian Academy of Pathology (USCAP), announces the following free articles in its April 2009 issue:
Endoscopic therapeutic modalities for neoplasms in Barrett's esophagus
Actinin-4 gene amplification in ovarian cancer
EML4-ALK-positive lung cancers FREE Cathepsin-K in lymphangioleiomyomatosis
Modern Pathology's main focus is original papers reporting innovative clinical and translational research in the pathology of human disease. Access to all content is FREE 12 months post-publication. Visit the journal website at www.modernpathology.org.
_______________________________________________
20 April 2009: Laboratory Investigation, the official journal of the United States and Canadian Academy of Pathology, presents the following free articles in its April 2009 issue:
A symptom-based approach to pharmacologic management of fibromyalgia
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
The Stigma of Obesity: A Review and Update
Laboratory Investigation is an international journal owned by The United States and Canadian Academy of Pathology and edited by a board appointed by the Council of the Academy. Laboratory Investigation offers prompt publication of high-quality original research in all biomedical disciplines relating to the understanding of human disease and the application of new methods to the diagnosis of disease. Visit online at Laboratory Investigation.
_______________________________________________
31 March 2009: Impac Software, part of the Elekta Group a provider of software solutions for anatomic pathology (AP) laboratories, and BioImagene, provider of innovative digital pathology solutions, announce the development of an interface between PowerPath®, Impac Software’s AP laboratory information system, and Virtuoso™, BioImagene’s digital pathology solution. The new interface provides an optimized workflow for digital slide imaging and analysis, case management and reporting. Dr. Ajit Singh, BioImagene CEO comments, “The Virtuoso PowerPath integration will benefit our laboratory customers further as they now have access to complete case history in a digital format improving the quality of results reported to the clinician.
For more information, please click here, or contact Julie DeSantis, Market Manager, Impac Software 408-830-8083 or jdesantis@impac.com, or call Robert Monroe, MD, PhD at 408-207-4283 or rmonroe@bioimagene.com.
__________________________________________
31 March 2009: Leica Microsystems announces that in 2008, for the first time in its history, its annual sales volume exceeded $1 billion. “We have substantially expanded our product breadth through a number of strategic company acquisitions,” comments Dr. David Martyr, President of Leica Microsystems. Leica Microsystems was purchased by Washington D.C.-based Danaher Corporation in the summer of 2005. Since that time, Leica Microsystems has acquired and integrated eight companies in Australia, Europe, the US, and Asia. Examples of innovation in life science include the super high-resolution STED technology that visualizes interactions in cellular structures of only a few nanometers and the Leica TCS LSI microscope system that enables bioscientists to perform single cell studies and research on entire organisms using just one instrument. Another recent innovation, FusionOpticsTM, reveals high-quality 3D images simultaneously in high resolution and high depth of field, which benefits the intricate work of life scientists and industrial quality control specialists alike.
For more information, please contact Dr. Kirstin Henze at kirstin.henze@leica-microsystems.com or click here.
_______________________________________________
16 March 2009: Impac Software, part of the Elekta Group, announces the introduction of PowerPath version 9.3. This includes updates to the Advanced Materials Processing module, which drives the workflow of a histology lab by tracking materials through the lab, from the receipt and processing of tissue specimens, through the creation and tracking of blocks and slides, to managing specimen discard. Batch processing has been added to the Document Management module to further streamline administrative tasks in the lab. The Digital Pathology Interface is bi-directional and keyed from the bar coded slides generated by PowerPath’s AMP module. Upon completion of the slide imaging event, slide thumbnails and region of interest images are sent to PowerPath to store with other case data. Users may also access experts from the PowerPath case by automatically linking to their PathIQ® ImmunoQuery® Custom Sync™ subscription.
For more information, please click here, or contact Julie DeSantis, Market Manager, Impac Software at 408-830-8083 or jdesantis@impac.com.
__________________________________________
25 February 2009: Voicebrook, a leading provider of integrated speech recognition solutions for healthcare, today announces the appointment of E. Bruce Sopko as Vice President, Sales. Sopko, who brings more than 20 years' experience, has a proven track record of driving market growth for speech recognition technologies in healthcare and brings strong leadership, operational, negotiation, creative and analytical skills.
For more information, please click here or email pathology@voicebrook.com.
_______________________________________________
12 February 2009: Quantimetrix Corporation announces its newly redesigned product packaging. Beginning in February, and over the next year, Quantimetrix will be phasing in the new box designs for all product lines. The changes have been made to the package alone, and not their products. The Quantimetrix catalog features urinalysis, general and specialty chemistry controls, whole blood, electrophoresis systems, diagnostic assays, and OEM products. The company’s catalog is available upon request by visiting www.4qc.com. or by calling 800.624.8380, ext. 183. Quantimetrix provides a comparative quality control program called Quantrol™. Free monthly reports are provided for participants allowing each lab to monitor test performance and trend analysis.
______________________________________________
10 February 2009: Covance is pleased to announce the availability of Collagen XVII antibody. Collagen XVII (BP180) is a transmembrane protein of the cutaneous basement membrane that plays an important role in epidermal-dermal adhesion. It has been associated with inherited bullous skin disease and autoimmune disease, and may also play a role in trophoblast invasion. The launch of Collagen XVII adds to Covance’s growing portfolio of antibodies and detection chemistries.
For more information, please visit www.covance.com.
_____________________________________________
10 February 2009: Vachette Pathology is proud to announce its newly improved website Vachettepathology.com. The website will have more content and more information. The goal of the website will be to concentrate all the knowledge and experience we have into a single database that is more useable for both our current and potential customers.
Vachette Pathology is a practice management firm that specializes in pathology. Currently we work with over 450 pathologists nationwide and are commonly held as the industry leaders in the business of pathology and laboratory management.
If you have any questions or for further information, please contact Mick Raich toll free at 866-407-0763, or email mraich@vachettepathology.com
_____________________________________________
17 November 2008: Milestone Medical introduces the Pathos Delta, the first hybrid rapid microwave tissue processor. Milestone has added resistant heat to its already successful open automated microwave processor. The addition of this technology allows for a wide range of workflow and protocol options for the laboratory. Uncompromised morphology, Xylene-free and Xylene protocols, delayed start, no reagent cleaning cycle and significantly less paraffin use are a few of the benefits of the system.
For more information call 866-995-5300, email info@milestonemed.com or click here.
_______________________________________________
18 September 2008: Invitrogen Corporation has signed an exclusive U.S. distribution agreement with Biocare Medical LLC for the new SPOT-Light® HER2 CISH Kit. The kit received U.S. Food and Drug Administration premarket approval in July, as an aid in the assessment of breast cancer patients for whom trastuzumab (Herceptin®) treatment is being considered.
Approximately one million people worldwide are screened each year for HER2 amplification or over-expression. The importance of genetic tests like HER2 CISH is growing because some targeted cancer therapies (like trastuzumab) are most effective in patients who overexpress the HER2 gene. The primary users will be pathologists, oncologists, and histotechnologists who will determine the best course of treatment for breast cancer patients. The SPOT-Light® test uses standard histology laboratory methods and equipment to yield valuable gene status information.
HER2 – not amplified HER2 - amplified
Per FDA requirements, laboratories must be certified prior to purchasing the SPOT-Light® HER2 CISH Kit for use on patient specimens. One user per laboratory must successfully complete Invitrogen’s HER2 CISH certification program. Full certification details are available by clicking here. After certification, the SPOT-Light® HER2 CISH Kit may be ordered by calling (800) 799-9499 or click here.
For more information, please visit Biocare at www.biocare.net or call 800-799-9499.
_______________________________________________
11 September 2008: AP Easy GYN Cytology Module is set to enter first round beta testing in early September 2008. It is expected to be widely available by November 2008. An updated version of Easy Billing insurance billing application and AP Easy to Easy Billing integration is on track for an early 2009 unveiling. For more information, please telephone 800-647-2263, email info@sbcne.com or click here.
_______________________________________________
10 September 2008: Sakura announces The Tissue-Tek® Xpress® x50. The Tissue-Tek® Xpress® x50 delivers unprecedented productivity and maximizes staff efficiency. The Tissue-Tek® Xpress® x50 processes up to 440 specimens in an 8-hour shift, with the ability to load up to 40 cassettes approximately every 45 minutes. It provides outstanding time and cost savings, as well as increased staff safety, while producing standardized, accurate results paralleling those from overnight processing, allowing same-day diagnosis and, ultimately, improved patient care.
For more information, visit us online (click here), write to mail@sakuraus.com, or call 1-800-725-8723 and press 1 for customer service.
_______________________________________________
9 September 2008: Pefachrome and Pefaflour peptide substrates are highly selective for the coagulation pathway and other serine protease activity. Centerchem is proud to announce the release of additional new chromogenic substrates for Thrombin, Factor Xa and Urokinase. These new substrates are the very same which are widely used in the biopharmaceutical industry, in clinical assay development and in research activities. As always, Centerchem is pleased to offer the same low prices and flexible packaging as we do on our wide range of other chromogenic and fluorogenic substrates
Visit www.centerchem.com, call 203-822-9800 or email diagnostics@centerchem.com for more information.
_______________________________________________
23 June 2008: ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, announced that it has entered into a business alliance with Pathology Service Associates, LLC (PSA), a nationwide network affiliation and a principal provider of business services and support to independent pathologist practices. The agreement offers special pricing to the over 400 pathologists affiliated with PSA for ARUP's esoteric molecular oncology and cytogenetics testing services. Additionally, ARUP's proprietary online diagnostic tool, ARUP Consult®, The Physician's Guide to Laboratory Test Selection and Interpretation, will be integrated into PSA's internal Web site for affiliated practices within the next few months.
For more information, click here, then click on News & Information on the right side.
_______________________________________________
18 June 2008. Lifepoint informatics announces the publication of its second quarter newsletter (click here). The newsletter contains articles about its upgraded phone system, Enhanced Manifest List and National Users Meeting. It discusses how its system design avoids problems during blackouts, and describes its partnership with Medlink to provide a sponsored MedLink EHR offering for laboratories.
The LifePoint mission is to assist and enable healthcare systems to offer convenient, timely and interactive results to electronic medical record systems, and receive pre-validated orders from their physician clients to satisfy the physician’s need to save time and improve patient satisfaction.
For more information, contact www.lifepoint.com, telephone: 866-LABTEST or email: jredding@labtest.com.
_______________________________________________
18 June 2007: Ventana Medical Systems announces its new CONFIRM anti-CD3 (2GV6) – the latest exciting advancement in moving from mouse to Rabbit Monoclonal Primary Antibodies.
CONFIRM anti-CD3 (2GV6) detects CD3 antigen expressed in the cytoplasmic membrane of normal and neoplastic T-cells.
To read a research paper about this product click here. For more information visit Ventanamed.com or call 800.227.2155.
End of New Products and Services page